Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome profiles of lymphoma cell lines after treatment with MZ1 compunds

ABSTRACT: Transcriptome profiles of lymphoma cell lines after treatment with MZ1 compunds

PROVIDER: PRJNA641082 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12067055.fastq.gz	Fastqsanger.gz
	SRR12067056.fastq.gz	Fastqsanger.gz
	SRR12067057.fastq.gz	Fastqsanger.gz

Items per page:

1 - 3 of 3

Similar Datasets

Transcriptome profiles of lymphoma cell lines after treatment with MZ1 compunds

Project description:4 lymphoma cell lines (DOHH2, OCILy10, TMD8 and Toledo) have been treated with MZ1. The transcriptome has been sequenced after 6hrs from the treatment

2023-06-01 | GSE152963 | GEO

Epigenetic treatment of B-cell lymphoma cell lines

Project description:We used DNA microarray technology to assess changes in gene expression after treatment of 11 lymphoma cell lines with epigenetic drugs. We identified genes with upregulated expression in treated cell lines and with downregulated expression in B-cell lymphoma patient samples when compared to normal B cells.

2013-04-18 | GSE46064 | GEO

Epigenetic treatment of B-cell lymphoma cell lines

2013-04-18 | E-GEOD-46064 | biostudies-arrayexpress

BRD4 inhibitor MZ1 exerts anti-cancer effects in Neuroblastoma

Project description:MZ1 is a newly designed pan-BET-targeting PROTAC that binds to target proteins (BET proteins such as BRD2, BRD3, and BRD4) and recruits them to the ubiquitin/protease pathway for selective destruction. However, the role of MZ1 in NB models has yet to be determined. The effect of MZ1 on NB cells was investigated using RNA-seq analysis in this work. MZ1 is a newly designed pan-BET-targeting PROTAC that binds to target proteins (BET proteins such as BRD2, BRD3, and BRD4) and recruits them to the ubiquitin/protease pathway for selective destruction. However, the role of MZ1 in NB models has yet to be determined. The effect of MZ1 on NB cells was investigated using RNA-seq analysis in this work.

2022-08-29 | GSE193767 | GEO

MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by targeting the super-enhancer-regulated gene SDC1 in Glioblastoma [RNA-Seq]

Project description:To investigate the function of MZ1 in the regulation of gene expression, we treated U87 cells with control (DMSO) or MZ1, respectively. We then performed gene expression profiling analysis using data obtained from RNA-seq of control and MZ1 treatment.

2023-10-16 | GSE244878 | GEO

Exploring the cytotoxic effects of MZ1 on multiple molecular subtypes of B-cell acute lymphoblastic leukemia cells

Project description:Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. B-cell acute myeloid leukemia (B-ALL) predominates in ALL, with current cure rates of ∼80%. However, the long-term survival rate of patients with early relapse or refractory B-ALL is very low. In recent years, Bromodomains and extra-terminal (BET) protein inhibitors have shown considerable prospect in hematological tumors. MZ1 is a novel BET inhibitor that degrades target proteins and inhibits tumor growth through proteolysis-targeting chimeras (PROTAC) technology. This study shows that MZ1 has cytotoxic effects on 697 (TCF3/PBX1) and RS4;11 (MLL-AF4) B-ALL cell lines representing different molecular subtypes of B-ALL. Furthermore, we observed that MZ1 could promote cell apoptosis, induce cells cycle arrest and inhibit B-ALL cell proliferation by depleting BET protein and downregulating the transcription of CCND3. Collectively, our results indicate that MZ1 might be exploited as a novel therapeutic strategy for the treatment of B-ALL.

2023-08-22 | GSE217540 | GEO

Staphylococcus sp. MZ1

Project description:Staphylococcus sp. MZ1 Genome sequencing

| PRJNA730223 | ENA

Transcriptional characterization of ABCC1 and ABCB1 KO and MZ1 treated WT HAP1 cell lines.

Project description:We used CRISPR/Cas9 to intoroduce frame-shifting mutations into the ABCC1 and ABCB1 genes and treated HAP1 WT cells with varying concentrations of the MZ1 PROTAC. To measure the transcriptional response to both genetic and chemical perturbances, we performed RNA-seq and quantified gene expression levels.

2023-06-07 | GSE234043 | GEO

RNA-Seq of a panel of human lymphoma cell lines (B cells)

Project description:We invastigated the baseline transcriptomic profiles of a panel of B-cell lymphoma cell lines

2023-05-10 | GSE221770 | GEO

murine MYC-dependent lymphoma cells: Dox vs. NoDox treatment

Project description:miRNA expression profiling of murine MYC-dependent lymphoma cell lines harboring the MYC-transgene in a Tet-off system comparing control untreated lymphoma cells (high MYC expression state) with 18hours Dox treated lymphoma cells (low MYC expression state). Keywords: inducible expression system Two-condition experiment, Dox vs. NoDox treatment. Biological replicates: 26 distinct cell lines, 1 technical replicate. Four replicates per array.

2010-05-25 | E-GEOD-12394 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data